Ayah Ghazi Al-Qasrawi: How Should Sepsis-Induced DIC Be Managed in Patients Receiving Thienopyridines
Ayah Ghazi Al-Qasrawi, Pediatric Resident at Jordanian Royal Medical Services, shared on LinkedIn:
”What is the appropriate management approach for a patient receiving thienopyridines (clopidogrel or prasugrel), which irreversibly inhibit the platelet P2Y12 receptor, who develops sepsis-induced disseminated intravascular coagulation (DIC)?
I think the platelet transfusion could be a part of treatment.
Thienopyridines such as Clopidogrel and Prasugrel irreversibly inhibit the platelet P2Y12 receptor, preventing ADP-mediated platelet activation and clot formation.
Because the inhibition is irreversible, the antiplatelet effect persists for the entire lifespan of the platelet, approximately 7–10 days.
Antiplatelet thienopyridines (such as clopidogrel and prasugrel) irreversibly affect platelet function, but they do not affect platelet count.
In severe sepsis–associated DIC, management should primarily focus on treating the underlying infection and correcting clinically significant coagulopathy.
Platelet transfusion may be considered when there is active bleeding, high bleeding risk, need for invasive procedures, or severe thrombocytopenia.
In patients receiving thienopyridines, transfused platelets may help restore hemostatic function because the newly transfused platelets are initially uninhibited.
However, platelet transfusion is not routinely indicated based only on abnormal laboratory findings and should be guided by the overall clinical picture, including bleeding severity, platelet count, ongoing consumption, and thrombotic risk.
Adjunctive therapies:
IVIG is generally not recommended for routine treatment of sepsis-associated DIC unless there is suspicion of an additional immune-mediated platelet disorder.
Desmopressin (DDAVP) may be considered in selected cases of significant antiplatelet-associated bleeding to improve platelet adhesion, although evidence remains limited and it is not standard therapy for DIC. ( I think )
Additional supportive measures such as fresh frozen plasma or cryoprecipitate may be required depending on PT/aPTT prolongation and fibrinogen levels.”
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 15:58Bernhard Merget: New Frontiers in Thrombosis and Stroke Research
-
Sep 30, 2026, 15:39Ifeanyichukwu Ifechidere: The Molecular Orchestra of Primary Hemostasis
-
Sep 30, 2026, 15:28Reassessing the Benefit–Risk Balance of Extended Anticoagulation in Cancer Patients – ESC Working Group on Cardiovascular Pharmacotherapy
-
Sep 30, 2026, 15:07Chiranjeev Sharma: Targeting Factor XIa with the Synthetic Inhibitor SB-01
-
Sep 30, 2026, 14:41Bruna Gigante: Balancing Thrombosis and Bleeding in Cardiovascular Care
-
Sep 30, 2026, 14:13Ashok Choudhury: Portal Vein Thrombosis and Outcomes in Cirrhosis
-
Sep 30, 2026, 13:57Leslye Conde Bazán: When Conventional Imaging Is Not Enough – The Role of IVUS
-
Sep 30, 2026, 13:41Huda Salah Eldin: The Challenge of Balancing Antithrombotic Therapy After PCI
-
Sep 30, 2026, 13:29Abdus Salam: What Can CT Venography Reveal About the Veins?